Daw-Tsun Shih

Title: The Innovations of Daw-Tsun Shih

Introduction

Daw-Tsun Shih is a prominent inventor based in Taipei, Taiwan. He has made significant contributions to the field of immunotherapy, particularly in the development of antibodies for treating cancer and viral infections. His innovative work has led to the filing of multiple patents, showcasing his expertise and dedication to advancing medical science.

Latest Patents

Daw-Tsun Shih holds 2 patents that focus on groundbreaking methods for treating diseases. His latest patents include the development of anti-colony stimulating factor 1 receptor (CSF1R) antibodies, which are designed to treat cancer by specifically binding to the human CSF1 receptor protein. These antibodies can effectively decrease, inhibit, and block immune regulatory effects mediated by huCSF1R, thereby enhancing CD8+ T-cell cytotoxicity in the tumor microenvironment. Additionally, he has developed methods for treating hepatitis B virus (HBV) infection using antibodies that specifically bind to human IFN-γ.

Career Highlights

Throughout his career, Daw-Tsun Shih has worked with notable companies, including Elixiron Immunotherapeutics Limited and Elixiron Immunotherapeutics (Hong Kong) Limited. His work in these organizations has been pivotal in advancing therapeutic strategies for various diseases.

Collaborations

Daw-Tsun Shih has collaborated with esteemed colleagues, including Hung-Kai Chen and Cheng-Lun Ku. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.

Conclusion

Daw-Tsun Shih's contributions to the field of immunotherapy through his patents and collaborations highlight his role as a leading inventor in medical science. His work continues to pave the way for new treatments that can significantly impact patient care.